Plasma copeptin levels and prediction of outcome in heart failure outpatients: Relation to hyponatremia and loop diuretic doses

Journal of Cardiac Failure

Volumn 18, Issue 5, 2012, Pages 351-358

  Balling, Louise ^a   Kistorp, Caroline ^b   Schou, Morten ^c   Egstrup, Michael ^d   Gustafsson, Ida ^b   Goetze, Jens Peter ^e   Hildebrandt, Per ^d   Gustafsson, Finn ^a  

^a University of Copenhagen   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c HILLERØD HOSPITAL   (Denmark)

^d FREDERIKSBERG HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

heart failure; hyponatremia; Vasopressin

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COPEPTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HORMONE PRECURSOR; LOOP DIURETIC AGENT; SODIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; BLOOD LEVEL; CONFOUNDING VARIABLE; CONTROLLED STUDY; DENMARK; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HOSPITALIZATION; HUMAN; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OUTPATIENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SYSTOLIC DYSFUNCTION;

AGED; BIOLOGICAL MARKERS; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLYCOPEPTIDES; HEART FAILURE; HUMANS; HYPONATREMIA; MALE; MORBIDITY; OUTPATIENTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SURVIVAL RATE; TIME FACTORS;

EID: 84860430800     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2012.01.019     Document Type: Article

References (35)

1. M. Packer The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure J Am Coll Cardiol 20 1992 248 254
2. G.L. Robertson, and S. Athar The interaction of blood osmolality and blood volume in regulating plasma vasopressin in man J Clin Endocrinol Metab 42 1976 613 620
3. K. Chatterjee Neurohormonal activation in congestive heart failure and the role of vasopressin Am J Cardiol 95 9A 2005 8B 13B
4. S.R. Goldsmith Vasopressin: a therapeutic target in congestive heart failure? J Card Fail 5 1999 347 356
5. J.G. Verbalis Vasopressin V2 receptor antagonists J Mol Endocrinol 29 2002 1 9
6. J.J. Preibisz, J.E. Sealey, J.H. Laragh, R.J. Cody, and B.B. Weksler Plasma and platelet vasopressin in essential hypertension and congestive heart failure Hypertension 5 2 Pt 2 1983 I129 I138
7. G. Baumann, and J.F. Dingman Distribution, blood transport, and degradation of antidiuretic hormone in man J Clin Invest 57 1976 1109 1116
8. N.G. Morgenthaler, J. Struck, C. Alonso, and A. Bergmann Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin Clin Chem 52 2006 112 119
9. S. Neuhold, M. Huelsmann, G. Strunk, B. Stoiser, J. Struck, and N.G. Morgenthaler Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease J Am Coll Cardiol 52 2008 266 272
10. B. Stoiser, D. Mortl, M. Hulsmann, R. Berger, J. Struck, and N.G. Morgenthaler Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure Eur J Clin Invest 36 2006 771 778
11. A. Gegenhuber, J. Struck, B. Dieplinger, W. Poelz, R. Pacher, and N.G. Morgenthaler Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure J Card Fail 13 2007 42 49
12. S.Q. Khan, O.S. Dhillon, R.J. O'Brien, J. Struck, P.A. Quinn, and N.G. Morgenthaler C-Terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study Circulation 115 2007 2103 2110
13. I. Tentzeris, R. Jarai, S. Farhan, T. Perkmann, M.A. Schwarz, and G. Jakl Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure Eur J Heart Fail 13 2011 726 733
14. L. De Luca, L. Klein, J.E. Udelson, C. Orlandi, G. Sardella, and F. Fedele Hyponatremia in patients with heart failure Am J Cardiol 96 12A 2005 19L 23L
15. L. Balling, M. Schou, L. Videbaek, P. Hildebrandt, H. Wiggers, and F. Gustafsson Prevalence and prognostic significance of hyponatraemia in outpatients with chronic heart failure Eur J Heart Fail 13 2011 968 973
16. V.D. Madan, E. Novak, and M.W. Rich Impact of change in serum sodium concentration on mortality in patients hospitalized with heart failure and hyponatremia Circ Heart Fail 4 2011 637 643
17. F. Gustafsson, H. Ulriksen, H. Villadsen, H. Nielsen, B.B. Andersen, and R. Hildebrandt Prevalence and characteristics of heart failure clinics in Denmark - design of the Danish Heart Failure Clinics Network Eur J Heart Fail 7 2005 283 284
18. F. Gustafsson, M. Schou, L. Videbaek, T. Nielsen, H. Ulriksen, and J. Markenvard Treatment with beta-blockers in nurse-led heart failure clinics: titration efficacy and predictors of failure Eur J Heart Fail 9 2007 910 916
19. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, D. Roth Modification of Diet in Renal Disease Study Group A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Ann Intern Med 130 1999 461 470
20. M. Madsen, M. Davidsen, S. Rasmussen, S.Z. Abildstrom, and M. Osler The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry J Clin Epidemiol 56 2003 124 130
21. N.G. Morgenthaler, J. Struck, S. Jochberger, and M.W. Dunser Copeptin: clinical use of a new biomarker Trends Endocrinol Metab 19 2008 43 49
22. M. Potocki, T. Breidthardt, A. Mueller, T. Reichlin, T. Socrates, and N. Arenja Copeptin and risk stratification in patients with acute dyspnea Crit Care 14 2010 R213 Epub 2010 Nov 24
23. T. Reichlin, W. Hochholzer, C. Stelzig, K. Laule, H. Freidank, and N.G. Morgenthaler Incremental value of copeptin for rapid rule out of acute myocardial infarction J Am Coll Cardiol 54 2009 60 68
24. W. Fenske, S. Stork, A. Blechschmidt, S.G. Maier, N.G. Morgenthaler, and B. Allolio Copeptin in the differential diagnosis of hyponatremia J Clin Endocrinol Metab 94 2009 123 129
25. S. Masson, R. Latini, E. Carbonieri, L. Moretti, M.G. Rossi, and S. Ciricugno The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-Heart Failure (GISSI-HF) trial Eur J Heart Fail 12 2010 338 347
26. U. Alehagen, U. Dahlstrom, J.F. Rehfeld, and J.P. Goetze Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure JAMA 305 2011 2088 2095
27. A. Maisel, Y. Xue, K. Shah, C. Mueller, R. Nowak, and W.F. Peacock Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study Circ Heart Fail 4 2011 613 620
28. G.S. Francis, C. Benedict, D.E. Johnstone, P.C. Kirlin, J. Nicklas, and C.S. Liang Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD) Circulation 82 1990 1724 1729
29. J. Rossi, M. Bayram, J.E. Udelson, D. Lloyd-Jones, K.F. Adams, and C.M. Oconnor Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial Acute Card Care 9 2007 82 86
30. L. Klein, C.M. O'Connor, J.D. Leimberger, W. Gattis-Stough, I.L. Pina, and G.M. Felker Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study Circulation 111 2005 2454 2460
31. M. Gheorghiade, J.S. Rossi, W. Cotts, D.D. Shin, A.S. Hellkamp, and I.L. Pina Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial Arch Intern Med 167 2007 1998 2005
32. A.I. Arieff, and R. Guisado Effects on the central nervous system of hypernatremic and hyponatremic states Kidney Int 10 1976 104 116
33. S.R. Goldsmith, G.S. Francis, A.W. Cowley Jr., I.F. Goldenberg, and J.N. Cohn Hemodynamic effects of infused arginine vasopressin in congestive heart failure J Am Coll Cardiol 8 1986 779 783
34. J. Perucca, D.G. Bichet, P. Bardoux, N. Bouby, and L. Bankir Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists J Am Soc Nephrol 19 2008 1721 1731
35. A. Maisel Biomonitoring and biomarker-guided therapy the next step in heart failure and biomarker research [editorial] J Am Coll Cardiol 58 2011 1890 1892